## Drug Summary
Rifapentine is an antibiotic primarily used for the treatment of tuberculosis. It operates by inhibiting DNA-dependent RNA polymerase in susceptible bacteria, specifically targeting Mycobacterium tuberculosis. This blockage prohibits RNA synthesis, essential for bacterial replication and survival, thereby displaying bactericidal activity. Rifapentine highlights a wide spectrum of activity against both gram-positive and gram-negative bacteria but is mainly restricted to mycobacterial infections due to the rapid development of resistance. It is rapidly absorbed from the gastrointestinal tract and demonstrates substantial distribution across body tissues, including the CSF. Metabolism occurs in the liver, primarily via hepatic pathways, with excretion mainly in the bile and, to a lesser extent, in urine. Notably, renal insufficiency does not necessitate dosage adjustments.

## Drug Targets, Enzymes, Transporters, and Carriers
The primary target of Rifapentine is the DNA-directed RNA polymerase subunit beta (rpoC) of Mycobacterium tuberculosis. This interaction leads to the suppression of RNA synthesis, critical for bacterial replication. Rifapentine does not affect the mammalian version of RNA polymerase, which underlines its specificity for bacterial cells. The drug is metabolized predominantly in the liver, implicating several cytochrome P450 enzymes which are crucial for its biotransformation. These include CYP2C19, CYP2B6, CYP3A4, CYP3A43, CYP3A5, CYP3A7, CYP2C8, and CYP2C9. No specific transporters or carriers are involved in its mechanism of action or pharmacokinetics based on the provided data.

## Pharmacogenetics
Rifapentine's metabolism is significantly influenced by various cytochrome P450 enzymes. The pharmacogenetic implications primarily revolve around CYP3A4 and CYP2C9, as variations in genes encoding these enzymes can affect drug levels and responses. For instance, individuals with certain polymorphisms in the CYP3A4 gene could either have higher or lower than expected drug concentrations, potentially impacting efficacy and toxicity. Similarly, variations in CYP2C9 might alter Rifapentine metabolism, influencing treatment outcomes. These genetic factors are vital considerations in optimizing dosing regimens and managing potential side effects, though specific recommended practices based on genetic variations are yet to be thoroughly established in clinical settings. Further genetic studies could provide more precise guidelines for the use of Rifapentine in individuals with specific genetic profiles.